Comparative evaluation of supplemental buccal infiltration adjuncts for enhancing inferior alveolar nerve block in symptomatic irreversible pulpitis: A randomized double-blind clinical study

辅助颊侧浸润麻醉剂增强下牙槽神经阻滞治疗症状性不可逆性牙髓炎的疗效比较评价:一项随机双盲临床研究

阅读:1

Abstract

BACKGROUND: Achieving profound pulpal anesthesia in mandibular molars with symptomatic irreversible pulpitis remains challenging, with inferior alveolar nerve block (IANB) failure rates up to 80%. This study evaluated the effect of supplemental buccal infiltration using tramadol, dexamethasone, ketorolac, and temperature-modified lidocaine on the efficacy of IANB. MATERIALS AND METHODS: In this randomized, double-blind clinical trial, 120 patients were allocated to six groups (n = 20 each): Control (IANB only), dexamethasone (4 mg/mL), ketorolac (30 mg/mL), tramadol (50 mg/mL), warm lidocaine (40°C), and cold lidocaine (4°C). All received 2% lidocaine with 1:200,000 epinephrine for IANB, followed by 1 mL of the assigned infiltration. Pain intensity was recorded using the Numeric Pain Rating Scale (0-10) during access, chamber, and canal entry. Anesthetic success was defined as a score <3 at canal entry. RESULTS: Anesthetic success rates were 90% (95% confidence interval [CI], 68%-99%) for tramadol, and 85% (95% CI, 62%-97%) for cold lidocaine, significantly higher than control (40%, P = 0.001 and P = 0.002, respectively). Dexamethasone (55%), ketorolac (50%), and warm lidocaine (60%) showed nonsignificant improvement (P > 0.05). Median pain scores were significantly lower in the tramadol and cold lidocaine groups across all the stages (P < 0.001). No adverse events occurred. CONCLUSION: Supplemental buccal infiltration with tramadol or cold lidocaine significantly enhances IANB success in mandibular molars with irreversible pulpitis, offering a simple, safe, and cost-effective approach to improve pulpal anesthesia.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。